| |
|
|
|
Nymox Pharmaceutical Corporation  
|
|
2.53 -0.01 (-0%) |
01-15 16:00 |
|
Open: |
2.6 |
Pre close: |
2.54 |
Target:
|
3.32
|
|
High: |
2.5953 |
Low: |
2.5 |
Resistance:
|
2.84
3.32
|
|
Volume: |
122,473 |
Market Cap: |
195M |
Support:
|
2.39
2.11
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
2.62
 |
MACD |
MACD(12,26):
|
0.09 |
|
MA(20): |
2.56  |
Signal(12,26,9): |
0.11 |
|
MA(100): |
2.33 |
Stochastic Oscillator |
%K(14,3):
|
43.95 |
|
MA(250): |
2.75 |
%D(3): |
58.70 |
|
Average Volume(K) |
3-Month: |
15198
|
52-Week |
High:
|
4.79 |
|
10-Days: |
12264 |
Low: |
1.66 |
|
RSI |
RSI(14):
|
52.03 |
Change(%): |
-15.7 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.172 |
Return on Equity (ttm) |
-261.2 |
Shares Out. (M) |
77.21 |
|
EPS Est. Current Year |
-0.200 |
Return on Assets (ttm) |
-117.5 |
Shares Float (M) |
43.42 |
|
EPS Est. Next Year |
-0.570 |
PEG Ratio |
0.00 |
% Held by Insiders |
43.56 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
6.80 |
|
Forward EPS |
-0.180 |
Gross Profit (p.s.) |
0.001 |
Shares Short (K) |
4100 |
|
Book Value (p.s.) |
0.050 |
EBITDA (p.s.) |
-0.167 |
P/E |
-14.71 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
50.60 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-10.17 |
P/S |
6301.33 |
|
Operating Margin |
-40038.71 |
Levered Free Cash Flow
(M) |
-5.88 |
P/CF |
-19.21 |
|
|
|
|
|
|
